<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880513</url>
  </required_header>
  <id_info>
    <org_study_id>CV-CORT-EX</org_study_id>
    <nct_id>NCT03880513</nct_id>
  </id_info>
  <brief_title>Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)</brief_title>
  <acronym>CV-CORT-EX</acronym>
  <official_title>Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Within this trial, the cardiovascular and mental status as well as the metabolic profiles of
      patients with endogenous cortisol excess are evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endogenous Cushing's syndrome (CS) is associated with increased cardiovascular (CV) morbidity
      and reduced general health status. It has been shown that these impairments may be reversible
      after cure of hypercortisolism. However, previous studies were restricted to selected CV
      aspects.

      The primary aim of the CV-CORT-EX study is to comprehensively assess left ventricular
      function and morphology of patients with endogenous CS. Secondly, we examine long-term
      changes of CV function, endothelial function, psychosocial status, bio-impedance, and quality
      of life.

      Within the longitudinal study, patients will be investigated at initial diagnosis and at
      least 6 months after cure of CS. Within the cross-sectional study, we aim to comprehensively
      phenotype patients with endogenous CS and unknown CV disease. Results will finally be
      compared with healthy controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>7 Years</target_duration>
  <primary_outcome>
    <measure>Cardiovascular status - pathological cardiac MRI</measure>
    <time_frame>7 years</time_frame>
    <description>Number of patients with pathological results (ejection fraction (&lt;55%), pericardial effusion, thrombus, adipose tissue, perfusion defects, late enhancement, valvular or wall motion abnormalities).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular status - pathological cardiac echocardiography</measure>
    <time_frame>7 years</time_frame>
    <description>Characterization of LV morphology and function, assessment of diastolic function and systolic strain. Assessment of regional and global LV function, characterization of right ventricular systolic function.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Endogenous Cushing's Syndrome</condition>
  <arm_group>
    <arm_group_label>Longitudinal study</arm_group_label>
    <description>Patients during overt and after cure of endogenous Cushing's syndrome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-sectional study</arm_group_label>
    <description>Patients with proven endogenous Cushing's syndrome (overt or subclinical).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiovascular status and quality of life</intervention_name>
    <description>Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment</description>
    <arm_group_label>Cross-sectional study</arm_group_label>
    <arm_group_label>Longitudinal study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cross-sectional study:

        - History of clinically and biochemically proven endogenous Cushing's syndrome (overt or
        subclinical)

        Longitudinal study:

        - Patients with clinically and biochemically proven endogenous Cushing's syndrome (initial
        diagnosis or recurrent disease)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥18 years

          -  Cross-sectional study:History of clinically and biochemically proven endogenous
             Cushing's syndrome (overt or subclinical)

          -  Longitudinal study: Patients with clinically and biochemically proven endogenous
             Cushing's syndrome (initial diagnosis or recurrent disease)

        Exclusion Criteria:

          -  Glucocorticoid pharmacotherapy for &gt;12 months within the previous 3 years

          -  Structural heart disease, chronic heart failure (&gt;NYHAII), systemic or single organ
             disease potentially affecting cardiac function

          -  Arterial hypertension (uncontrolled with &gt;3 antihypertensive drugs)

          -  Pregnancy

          -  Drug abuse

          -  Cardiac Magnetic Resonance Imaging (cMRI) substudy: patients with renal failure are
             excluded from the cMRI study (MDRD &lt;60)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Fassnacht, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Wuerzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timo Deuschbein, MD</last_name>
    <phone>+4993120139200</phone>
    <email>deutschbein_t@ukw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Hahner, Professor</last_name>
    <phone>+4993120139200</phone>
    <email>hahner_s@ukw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timo Deutschbein, MD</last_name>
      <phone>+4993120139200</phone>
      <email>deutschbein_T@ukw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kamenický P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z, Macron L, Guignat L, Jublanc C, Azarine A, Brailly S, Young J, Mousseaux E, Chanson P. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab. 2014 Nov;99(11):E2144-53. doi: 10.1210/jc.2014-1783. Epub 2014 Aug 5.</citation>
    <PMID>25093618</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endogenous Cushing's Syndrome</keyword>
  <keyword>Cardiovascular status</keyword>
  <keyword>Metabolic profile</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

